Is CORT a Buy? What to Consider in 2026

Last updated July 2026

Short answer

The bull case for Corcept Therapeutics (CORT) rests on Cushing's / hypercortisolism growth runway: Corcept has spent years educating endocrinologists that hypercortisolism is underdiagnosed, and that effort is showing up in record new-patient starts and record new prescribers. Revenue (TTM) is ~$770M. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Revenue concentration is the defining risk: Korlym still drives the overwhelming majority of sales, and a court ruling has cleared a path for Teva's generic mifepristone, which could erode the flagship franchise faster than the new products scale. Whether CORT is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.

Corcept Therapeutics is a commercial-stage pharmaceutical company focused on disorders driven by excess cortisol activity. Its foundation is Korlym (mifepristone), a glucocorticoid receptor modulator approved for hypercortisolism (Cushing's syndrome), which generated the bulk of its ~$761 million in 2025 revenue. The company has spent years building physician awareness that hypercortisolism is more common than historically recognized, driving record new-patient starts, and it is expanding beyond a single product: the FDA approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer in March 2026, and Corcept resubmitted a New Drug Application for relacorilant in Cushing's syndrome in June 2026. The investment picture is unusual for biotech: Corcept is consistently profitable, carries zero debt, and held roughly $515 million in cash and investments as of March 2026. Management raised full-year 2026 revenue guidance to a $950 million to $1.05 billion range. The counterweight is concentration and legal risk. A court ruling cleared a path for Teva's generic version of Korlym, threatening the franchise that still funds nearly everything, so the bull case rests on relacorilant approvals and the oncology pipeline replacing and outgrowing branded Korlym before generic erosion bites.

What's the case for buying CORT?

1. Cushing's / hypercortisolism growth runway

Corcept has spent years educating endocrinologists that hypercortisolism is underdiagnosed, and that effort is showing up in record new-patient starts and record new prescribers. The 2025 franchise grew tablets sold by roughly 37 percent year over year, and management has cited capacity constraints (not demand) as a past limiter, suggesting room to convert latent demand into revenue.

2. Relacorilant as the next-generation successor

Relacorilant is Corcept's proprietary, patent-protected selective cortisol modulator designed to avoid mifepristone's off-target effects. Corcept resubmitted its Cushing's NDA in June 2026 after an earlier complete response letter. If approved, relacorilant could migrate the Cushing's base onto a differentiated, longer-dated-IP molecule and blunt the impact of generic Korlym.

3. Oncology optionality via Lifyorli

The March 2026 FDA approval of Lifyorli (relacorilant) for platinum-resistant ovarian cancer opened a second commercial franchise, with U.S. sales beginning in April 2026. Corcept is running additional cortisol-modulation studies across ovarian, endometrial, cervical, pancreatic and other solid tumors, giving the story a pipeline that is independent of the Cushing's cash cow.

4. Self-funded, debt-free balance sheet

Unlike most clinical-stage biotech, Corcept funds its trials and launches from operating cash flow rather than dilution or debt. With no debt and roughly half a billion dollars in cash and investments, it can absorb heavy launch spending (Lifyorli commercialization pushed it to a Q1 2026 loss) without an urgent financing need.

What are the risks to CORT?

Revenue concentration is the defining risk: Korlym still drives the overwhelming majority of sales, and a court ruling has cleared a path for Teva's generic mifepristone, which could erode the flagship franchise faster than the new products scale. Relacorilant approval is not guaranteed, as evidenced by an earlier FDA complete response letter before the June 2026 resubmission. Teva has also raised antitrust-style allegations about Corcept's distribution and patent practices, adding litigation overhang. The stock trades at a rich trailing earnings multiple, so any disappointment in guidance, approvals, or generic timing can drive sharp drawdowns, and the oncology launch is early and unproven at scale.

How is CORT valued? (as of July 2026)

Price

$95.36

Market cap

$10.24B

P/E (TTM)

280.47

Forward P/E

29.74

Price / book

16.04

Beta

0.46

52-week range

$28.66 to $97.63

Snapshot for CORT as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$770M
FY2025 revenue: ~$761M
FY2026 revenue guidance: ~$950M to $1.05B
Market cap: ~$9.4B
P/E (TTM): ~50x
Cash & investments / debt: ~$515M / no debt

Corcept is profitable on a full-year basis but posted a Q1 2026 net loss of roughly $32 million as it ramped Lifyorli launch spending (SG&A near $145 million, R&D near $66 million). The trailing P/E near 50x reflects a growth-and-optionality premium rather than a value multiple. The zero-debt balance sheet and half-billion-dollar cash cushion give it flexibility to fund launches and litigation internally.

How do you decide if CORT is a buy?

Rather than asking whether CORT is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold CORT indirectly through an index or sector ETF before adding more.

For the full picture, see the CORT stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CORT against your real portfolio and see your actual exposure before deciding.

The bottom line on CORT

The bottom line: Corcept Therapeutics's story right now is Cushing's / hypercortisolism growth runway, with revenue (ttm) at ~$770M. If you believe that narrative continues, the call is about sizing CORT sensibly and checking overlap with what you own; if you doubt it (the risk: revenue concentration is the defining risk: Korlym still drives the overwhelming majority of sales, and a court ruling has cleared a path for Teva's generic mifepristone, which could erode the flagship franchise faster than the new products scale.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.

More on CORT

CORT stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
CORT stock forecast (the drivers and risks shaping the outlook)
Does CORT pay a dividend?

Build a basket around CORT with Walnut

Use Corcept Therapeutics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.

Create a free Walnut account

FAQ

Is CORT a good stock to buy right now?

The case for Corcept Therapeutics right now is Cushing's / hypercortisolism growth runway, with revenue (ttm) at ~$770M. If you believe that thesis holds, CORT is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is revenue concentration is the defining risk: Korlym still drives the overwhelming majority of sales, and a court ruling has cleared a path for Teva's generic mifepristone, which could erode the flagship franchise faster than the new products scale. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.

What does Corcept Therapeutics do?

Corcept Therapeutics is a commercial-stage pharmaceutical company focused on disorders driven by excess cortisol activity.

What are the main risks of CORT?

What does Corcept Therapeutics actually sell?

Its main product is Korlym (mifepristone), a cortisol-blocking drug approved for hypercortisolism in Cushing's syndrome, which drives most of its revenue. In March 2026 the FDA also approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer, adding a second commercial product.

Is Corcept profitable?

Yes, on a full-year basis. It generated roughly $761 million in 2025 revenue and has been consistently profitable, though it reported a Q1 2026 net loss of about $32 million because of heavy spending to launch Lifyorli. It carries no debt and holds around $515 million in cash and investments.

What is the biggest risk to CORT?

Revenue concentration in Korlym combined with generic competition. A court ruling cleared a path for Teva's generic mifepristone, which could erode the franchise that funds most of the company before newer products fully scale.

What is relacorilant and why does it matter?

Relacorilant is Corcept's proprietary, next-generation selective cortisol modulator with longer-dated patent protection than Korlym. It is already approved as Lifyorli in ovarian cancer, and Corcept resubmitted a New Drug Application for it in Cushing's syndrome in June 2026 after an earlier FDA complete response letter.

Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell CORT; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.